Month: April 2026

Festi’s operations in line with expectations – Q1 profit amounted to ISK 218 million Main results in Q1 2026Sales of goods amounted to ISK 40,061 million, an increase of 6.0% YoY. Margin from sales of goods and services amounted to ISK 9,747 million, an increase of 5.8% YoY. Gross margin was 24.3%, decreasing by 0.1 p.p. from Q1 2025, but by 0.6 p.p. excluding the effects of exchange rates, changes in global fuel markets and changes in public levies on fuel at the turn of the year. EBITDA amounted to ISK 2,565 million, increasing by 3.0% YoY. Profit amounted to ISK 218 million and return on equity was 13.7%. Net cash from operating activities was negative by ISK 32 million, with one-off effects in operating-related assets and liabilities explaining the YoY difference. Interest-bearing debt was refinanced during the quarter for approximately...

Q1 revenue of €203.3 million, down -8.6%Stronger seasonality due to unfavorable weather conditions at the start of the year, especially in Germany, Poland, and for the Energy activities in FranceConnectivity in France (13% of group revenue): continuation of accelerated adaptation measuresRevenue down -29.9% in Q1 First structural actions launched at the end of 2025 completed under good execution conditions Continued reduction of exposure to least profitable activitiesSolid fundamentals across the rest of the GroupEnergy becomes Solutions30’s largest revenue contributor in France, in well-oriented markets Gradual resumption of fiber roll-out in Belgium Strong positioning with established telecom service providers in Germany, in a market undergoing structuring  Q1In millions of euros 2026 2025 restated* % changeGroup 203.3 222.3         -8.6%Benelux 81.6 88.7         -8.0%France 69.8 76.3         -8.6%Germany 19.0 21.9         -13.5%Other...

Clermont-Ferrand – April 29, 2026 COMPAGNIE GÉNÉRALE DES ÉTABLISSEMENTS MICHELIN Financial information for the three months ended March 31, 2026 Michelin delivered a solid performance in the first quarter, the decline in revenue reflecting changes in exchange rates. In a highly uncertain environment, the Group is adapting its steering and maintaining its 2026 guidance. Group revenue amounted to €6.2 billion for the quarter, down 5.4% on a reported basis but stable at constant exchange ratesCurrency effect accounted for the entire decline, reflecting euro’s strong appreciation against US dollar and most currencies. Tire sales reported a modest decline in volume (-1.4%), confirming the positive trend observed in the fourth quarter of 2025. Replacement sales increased, boosted by a strong performance from the MICHELIN brand (+3% in...

Enrolment completed in Phase 2 part of head and neck cancer clinical trial (TG4050) – Topline data expected by the end of Q1 2028 as per plan Phase 1 data from TG4050 in head and neck cancer published on medRxiv License agreement signed with NEC Bio to advance clinical development of TG4050 in head and neck cancer Financial visibility until early 2028Strasbourg, France, April 29, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today provides a business update on its myvac® platform, and its individualized neoantigen therapeutic vaccine (INTV) TG4050, and upcoming plans, including its financial position as of March 31, 2026. TG4050, Transgene’s first INTV from its myvac® platform continues to progress according to plan in the adjuvant...